Supportive Care in Cancer

, Volume 20, Issue 7, pp 1585–1587

Lenalidomide cutaneous adverse event: a case of Stevens–Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone

  • A. Siniscalchi
  • A. Tendas
  • L. Morino
  • T. Dentamaro
  • A. De Bellis
  • A. Perrotti
  • P. de Fabritiis
  • P. Musto
  • T. Caravita
Short Communication

Keywords

Lenalidomide Stevens–Johnson syndrome Plasma cells leukaemia 

References

  1. 1.
    Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A (2008) Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR Study. J Invest Dermatol 128:35–44PubMedCrossRefGoogle Scholar
  2. 2.
    Becker DS (1998) Toxic epidermal necrolysis. Lancet 351:1417–1420PubMedCrossRefGoogle Scholar
  3. 3.
    Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC (2002) Correlations between clinical patterns and causes of erythema multiforme majus, Stevens–Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 138:1019–1024PubMedCrossRefGoogle Scholar
  4. 4.
    Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC (1993) A clinical classification of cases of toxic epidermal necrolysis, Stevens–Johnson syndrome and erythema multiforme. Arch Dermatol 129:92–96PubMedCrossRefGoogle Scholar
  5. 5.
    Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern S, Anderson T et al (1995) Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333:1600–1607PubMedCrossRefGoogle Scholar
  6. 6.
    Castaneda CP, Brandenburg NA, Bwire R, Burton GH, Zeldis JB (2009) Erythema multiforme/Stevens–Johnson syndrome/toxic epidermal necrolysis in lenalidomide-treated patients. J Clin Oncol 27(1):156–157PubMedCrossRefGoogle Scholar
  7. 7.
    Lowndes S, Darby A, Mead G, Lister A (2002) Stevens–Johnson syndrome after treatment with rituximab. Ann Oncol 13:1948–1950PubMedCrossRefGoogle Scholar
  8. 8.
    Sanchez-Gonzalez B, Pascual-Ramirez JC, Fernandez-Abellan P, Belinchon-Romero I, Rivas C, Vegara-Aguilera G (2003) Severe skin reaction to imatinib in a case of Philadelphia-positive lymphoblastic leukemia. Blood 101:2446PubMedCrossRefGoogle Scholar
  9. 9.
    Fang B, Song Y, Ma J, Zhao RC (2007) Severe epidermal necrolysis after bortezomib treatment for multiple myeloma. Acta Haematol 118:65–67PubMedCrossRefGoogle Scholar
  10. 10.
    Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, Lust JA, Russell SJ, Kyle RA, Witzig TE, Gertz MA (2005) Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106(13):4050–4053PubMedCrossRefGoogle Scholar
  11. 11.
    Sviggum HP, Davis MDP, Rajkumar V, Dispenzieri A (2006) Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol 142:1298–1302PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • A. Siniscalchi
    • 1
  • A. Tendas
    • 1
  • L. Morino
    • 1
  • T. Dentamaro
    • 1
  • A. De Bellis
    • 3
  • A. Perrotti
    • 1
  • P. de Fabritiis
    • 1
  • P. Musto
    • 2
  • T. Caravita
    • 1
  1. 1.Department of Hematology, S. Eugenio Hospital“Tor Vergata” UniversityRomeItaly
  2. 2.Unit of Hematology and Stem Cell TransplantationIRCCS, Centro di Riferimento Oncologico della BasilicataRionero in VultureItaly
  3. 3.Department of Plastic, Reconstructive and Aesthetic SurgeryS. Eugenio HospitalRomeItaly

Personalised recommendations